Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Updates from ASH in CLL therapy: big trials, big results

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, of the University of Leeds, Leeds, UK, shares an overview of key updates in treatment for chronic lymphocytic leukemia (CLL), including the MURANO (NCT02005471), iLLUMINATE (NCT02264574), ALLIANCE A041202 (NCT01886872), and ECOG-E1912 (NCT02048813) studies, aiming to uncover the most effective initial therapy for CLL. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Hillmen describes the superiority of frontline targeted treatments compared with chemotherapy.